Trials / Completed
CompletedNCT00191607
A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.
A Randomized Phase III Trial of Gemzar Versus Doxil With Crossover Treatment Option for Patients With Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Undergoing Second or Third-Line Chemotherapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 162 (planned)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial compares two chemotherapy agents for the treatment of recurrent ovarian, fallopian or primary peritoneal cancer in patients that have received and are no longer responding to Platinum based treatment. The purpose of this trial is to compare progression free survival between gemcitabine and liposomal doxorubicin. Progression free survival (PFS) is defined as the period from study entry until disease progression
Conditions
- Genital Neoplasms, Female
- Fallopian Tube Neoplasms
- Ovarian Neoplasms
- Pelvic Neoplasms
- Peritoneal Neoplasms
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gemcitabine | |
| DRUG | liposomal doxorubicin |
Timeline
- Start date
- 2002-07-01
- Completion
- 2005-11-01
- First posted
- 2005-09-19
- Last updated
- 2007-01-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00191607. Inclusion in this directory is not an endorsement.